Clinical trial
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer…
NCT00270894 · Accelerated Community Oncology Research Network, Other · Completed
Key facts
| NCT number | NCT00270894 |
|---|---|
| Title | Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients |
| Official title | Pilot Trial of Sequential Dose-Dense Neoadjuvant Chemotherapy Plus Herceptin in HER2 Positive Stage II-III Breast Cancer Patients |
| Lead sponsor | Accelerated Community Oncology Research Network, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasm |
| Intervention type | Drug |
| Interventions | epirubicin, cyclophosphamide, docetaxel, trastuzumab |
| Enrollment | 30 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Dec 29, 2005 |
| Last update posted | Mar 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: